Gilles Avenard

Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT017, an Antiplatelet GPVI (Glycoprotein VI) Fab

Christine Voors‐Pette, Kristell Lebozec, Peter Dogterom et al. · Arteriosclerosis Thrombosis and Vascular Biology · 2019 · 111 citations · Full text

Design, development and characterization of ACT017, a humanized Fab that blocks platelet's glycoprotein VI function without causing bleeding risks

Kristell Lebozec, Martine Jandrot‐Perrus, Gilles Avenard et al. · mAbs · 2017 · 89 citations · Full text

Safety and efficacy of platelet glycoprotein VI inhibition in acute ischaemic stroke (ACTIMIS): a randomised, double-blind, placebo-controlled, phase 1b/2a trial

Mikaël Mazighi, Martin Köhrmann, Robin Lemmens et al. · The Lancet Neurology · 2024 · 57 citations · Full text

Thrombosis, Ischemic Stroke, Cardiovascular Disease +10

Large scale detection of IgA deficient blood donors

C. Ropars, Anne Müller, N. Paint et al. · Journal of Immunological Methods · 1982 · 45 citations

Transplantation, Medicine, Immunology +7

Quality and cost assessment of a recombinant antibody fragment produced from mammalian, yeast and prokaryotic host cells: A case study prior to pharmaceutical development

Kristell Lebozec, Martine Jandrot‐Perrus, Gilles Avenard et al. · New Biotechnology · 2018 · 39 citations

Recombinant Antibody Fragment, Pharmaceutical Development, Cost Assessment +8